- Home
- ZURA vs CRUS Comparison
ZURA vs CRUS Comparison
Compare ZURA & CRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZURA
- CRUS
- Stock Information
- Founded
- ZURA 2022
- CRUS 1984
- Country
- ZURA United States
- CRUS United States
- Employees
- ZURA 30
- CRUS N/A
- Industry
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- CRUS Semiconductors
- Sector
- ZURA Health Care
- CRUS Technology
- Exchange
- ZURA Nasdaq
- CRUS Nasdaq
- Market Cap
- ZURA 76.6M
- CRUS N/A
- IPO Year
- ZURA N/A
- CRUS 1989
- Fundamental
- Price
- ZURA $1.23
- CRUS $85.58
- Analyst Decision
- ZURA Buy
- CRUS Strong Buy
- Analyst Count
- ZURA 7
- CRUS 6
- Target Price
- ZURA $14.67
- CRUS $128.67
- AVG Volume (30 Days)
- ZURA 401.0K
- CRUS 787.3K
- Earning Date
- ZURA 05-08-2025
- CRUS 05-06-2025
- Dividend Yield
- ZURA N/A
- CRUS N/A
- EPS Growth
- ZURA N/A
- CRUS 75.79
- EPS
- ZURA N/A
- CRUS 5.50
- Revenue
- ZURA N/A
- CRUS $1,843,448,000.00
- Revenue This Year
- ZURA N/A
- CRUS $5.60
- Revenue Next Year
- ZURA N/A
- CRUS $0.26
- P/E Ratio
- ZURA N/A
- CRUS $15.57
- Revenue Growth
- ZURA N/A
- CRUS 2.99
- 52 Week Low
- ZURA $0.97
- CRUS $75.83
- 52 Week High
- ZURA $6.35
- CRUS $147.46
- Technical
- Relative Strength Index (RSI)
- ZURA 49.62
- CRUS 39.18
- Support Level
- ZURA $1.06
- CRUS $83.04
- Resistance Level
- ZURA $1.32
- CRUS $88.98
- Average True Range (ATR)
- ZURA 0.15
- CRUS 5.34
- MACD
- ZURA 0.01
- CRUS -0.23
- Stochastic Oscillator
- ZURA 68.42
- CRUS 39.31
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.